The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population
Clin Gastroenterol Hepatol. 2021 May 25;S1542-3565(21)00573-5.doi: 10.1016/j.cgh.2021.05.035. Online ahead of print.
Scott McHenry1, Yikyung Park2, Nicholas O Davidson3
Author information
1Division of Gastroenterology, Department of Medicine, Washington University in Saint Louis, St. Louis, Missouri. Electronic address: smchenry@wustl.edu.
2Division of Public Health Sciences, Department of Surgery, Washington University in Saint Louis, St. Louis, Missouri.
3Division of Gastroenterology, Department of Medicine, Washington University in Saint Louis, St. Louis, Missouri.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a global public health crisis that affects one quarter of the world population.1 Preventing either cardiometabolic or liver-related complications by achieving weight loss and resolving hepatic steatosis would be the central goal of a NAFLD screening program in the primary care setting. Despite the overwhelming prevalence and the multimodal impact on health posed by NAFLD, specialty society guidelines do not recommend screening for NAFLD in the general population,2 partly owing to the as-yet unproven cost benefit.